Lesson plan
Adrogolide
Adrogolide ( ; developmental code names A-93431, ABT-431, and DAS-431), also known as adrogolide hydrochloride ( ) in the case of the hydrochloride salt, is a dopamine D 1 -like receptor agonist which was under development for the treatment of Parkinson's disease, cognition disorders, and cocaine-related disorders but was never marketed. It is a chemically stable and rapidly converted diacetate ester prodrug of the highly selective dopamine D 1 and D 5 receptor full agonist A-86929. The effects of adrogolide and A-86929 in animals and humans have been studied. Side effects of adrogolide in humans included injection site reactions, asthenia, headache, nausea, vomiting, postural hypotension, vasodilation, and dizziness. Adrogolide was under development by Abbott Laboratories and DrugAbuse Sciences. It reached phase 2 clinical trials for Parkinson's disease prior to the discontinuation of its development in 2001. The drug is said to have been the first extensively characterized dopamine D 1 receptor full agonist.
Article summary
Adrogolide ( ; developmental code names A-93431, ABT-431, and DAS-431), also known as adrogolide hydrochloride ( ) in the case of the hydrochloride salt, is a dopamine D 1 -like receptor agonist which was under development for the treatment of Parkinson's disease, cognition disorders, and cocaine-related disorders but was never marketed. It is a chemically stable and rapidly converted diacetate ester prodrug of the highly selective dopamine D 1 and D 5 receptor full agonist A-86929. The effects of adrogolide and A-86929 in animals and humans have been studied. Side effects of adrogolide in humans included injection site reactions, asthenia, headache, nausea, vomiting, postural hypotension, vasodilation, and dizziness. Adrogolide was under development by Abbott Laboratories and DrugAbuse Sciences. It reached phase 2 clinical trials for Parkinson's disease prior to the discontinuation of its development in 2001. The drug is said to have been the first extensively characterized dopamine D 1 receptor full agonist.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.